Study guide

Screening, SBIRT & the ASAM Criteria Levels of Care

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

Screening, SBIRT & the ASAM Criteria Levels of Care

Key Takeaways Explain This Topic AI

Screen, assess and diagnose is the single largest CARN-AP activity area at 30% of items, or roughly 44 to 46 of 150 questions.

SBIRT separates universal screening from brief intervention (5 to 15 minutes, motivational) and referral to treatment, and is designed for general medical settings rather than addiction specialty care.

The ASAM Criteria assess six dimensions and place patients across five broad levels of care from Level 0.5 early intervention to Level 4 medically managed intensive inpatient.

Dimension 1 (acute intoxication/withdrawal potential) and Dimension 3 (emotional, behavioral or cognitive conditions) most often drive an increase in level of care.

A level-of-care recommendation must reflect the patient's actual dimensional needs, not bed availability, insurance preference, or the patient's request — documenting the mismatch is the APRN's obligation when the recommended level is unavailable.

Last updated: September 2026

Screening, SBIRT & the ASAM Criteria Levels of Care

Quick Answer: SBIRT — Screening, Brief Intervention, and Referral to Treatment — is the public-health model for detecting unhealthy substance use in general medical settings. Screening uses brief validated instruments ( AUDIT-C , single-item alcohol or drug screen , DAST-10 , TAPS , CRAFFT for adolescents); brief intervention is a 5- to 15-minute motivational conversation ; referral to treatment is reserved for patients meeting criteria for a substance use disorder. The ASAM Criteria then match a patient to a level of care using six assessment dimensions , producing placements from Level 0.5 (early intervention) through Level 4 (medically managed intensive inpatient) .

1. Why This Section Carries the Most Weight

Activity Area I — screen, assess and diagnose the processes and complications of substance-related and addictive disorders — is 30% of the CARN-AP , about 44 to 46 items . The highest-rated activity within it is “utilizes complex data and information obtained during interviews, examinations, and diagnostic processes when identifying diagnoses” (mean index 10.67). Exam items in this area rarely ask you to recall a cutoff in isolation; they give you interview data, physical findings and labs, then ask what the data mean together.

2. Screening Instruments Worth Knowing Cold

  • Instrument Target Length Common threshold
  • AUDIT Alcohol use, past year 10 items 8 or more suggests hazardous use; 20 or more suggests likely dependence
  • AUDIT-C Alcohol consumption only 3 items 4 or more in men, 3 or more in women

Single-Item Alcohol Screen Heavy drinking days 1 item Any report of 5 or more drinks (men) or 4 or more (women) in a day in the past year

  • CAGE Lifetime alcohol problems 4 items 2 or more; poor sensitivity for current hazardous drinking
  • DAST-10 Drug use, past year 10 items 3 or more suggests moderate problems

TAPS Tool Tobacco, alcohol, prescription and other substances 4-item screen plus brief assessment Any positive triggers the substance-specific module

CRAFFT Adolescents, all substances 6 items 2 or more warrants full assessment

NIDA Quick Screen / ASSIST All substances, risk tiers Variable ASSIST specific substance involvement score guides intervention level

Exam trap: CAGE asks about lifetime problems and is insensitive to current hazardous drinking, particularly in women and older adults. When a stem describes a patient with recent heavy drinking but no history of guilt or eye-openers, a negative CAGE does not rule out an alcohol use disorder — AUDIT-C or a single-item heavy-drinking-day question is the better screen.

3. SBIRT in Practice

Screening. Universal, not targeted. Applying screening only to patients who “look like” they use substances reproduces bias and misses the majority of unhealthy use, which occurs in employed, insured, socially stable people.

Brief Intervention. A structured 5- to 15-minute motivational conversation. The FRAMES elements — F eedback, R esponsibility, A dvice, M enu of options, E mpathy, S elf-efficacy — remain the most testable summary. Brief intervention has its strongest evidence for unhealthy alcohol use that does not meet criteria for a disorder ; it is not a substitute for treatment of moderate-to-severe substance use disorder.

Referral to Treatment. Indicated when the assessment supports a diagnosis requiring specialty care. A warm handoff — direct introduction to the receiving clinician while the patient is still present — substantially outperforms a phone number on discharge paperwork.

A high-yield nuance: brief intervention alone has repeatedly failed to change outcomes for drug use (as distinct from alcohol) in primary care trials. On the exam, a patient with a moderate or severe opioid or stimulant use disorder needs treatment engagement and, where indicated, medication — not a brief intervention.

4. The Six ASAM Dimensions

Dimension What it assesses Example of what raises level of care

1. Acute intoxication and/or withdrawal potential Current intoxication, withdrawal risk, prior severe withdrawal History of withdrawal seizures or delirium tremens

2. Biomedical conditions and complications Physical health problems needing concurrent care Untreated endocarditis, poorly controlled diabetes, advanced pregnancy

3. Emotional, behavioral or cognitive conditions and complications Psychiatric symptoms, suicidality, cognitive impairment Active suicidal ideation with plan; acute psychosis

4. Readiness to change Motivation, engagement, awareness Externally coerced with no internal motivation

5. Relapse, continued use or continued problem potential Craving severity, relapse history, coping skills Repeated relapse within days of leaving lower levels

6. Recovery/living environment Housing, safety, support, transportation Unhoused; living with an actively using partner; domestic violence

5. Levels of Care

  • Level Setting Typical intensity
  • 0.5 Early intervention Education and brief intervention for at-risk use without a diagnosis
  • 1 Outpatient Fewer than 9 hours per week of structured services for adults
  • 2.1 Intensive outpatient 9 or more hours per week for adults
  • 2.5 Partial hospitalization 20 or more hours per week with daily clinical access

3 (3.1–3.7) Residential/inpatient From clinically managed low-intensity residential through medically monitored intensive inpatient

4 Medically managed intensive inpatient 24-hour nursing with physician availability; acute hospital level

Withdrawal management runs on a parallel track across these levels — ambulatory withdrawal management with or without extended on-site monitoring, clinically managed residential withdrawal management, and medically monitored or medically managed inpatient withdrawal management.

6. Making — and Defending — a Placement Decision

Three rules that recur as exam answers:

The highest-acuity dimension drives the placement. A patient who is medically stable, motivated and housed but has a documented history of withdrawal seizures is placed on Dimension 1 severity, not on the average of the six dimensions.

Placement follows assessment, not availability. When the indicated level of care is unavailable, the APRN documents the recommended level, the reason it could not be provided, the interim plan, and the specific conditions that should trigger escalation. Writing a lower level of care into the record because a bed is unavailable misrepresents the assessment.

Readiness to change modifies the plan, not the diagnosis. Low readiness (Dimension 4) calls for motivational strategies and often a more supportive level of care — it is never grounds for discharging a patient as “not ready for treatment.”